Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1148 | 1013 | 1320 | 986 | 1788 | 3020 |
Fund Return | 14.75% | 1.25% | 31.99% | -0.47% | 12.32% | 11.69% |
Place in category | 1057 | 2040 | 1350 | 1454 | 262 | 39 |
% in Category | 39 | 72 | 49 | 60 | 16 | 6 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
TRUS Smaller Companies Equity Funda | 4.95B | 6.31 | 0.53 | 10.22 | ||
TRUS Smaller Companies Equity Fundi | 4.95B | 7.08 | 1.33 | 11.03 | ||
TRUS Smaller Companies Equity Fundq | 4.95B | 7.05 | 1.28 | 10.96 | ||
T Rowe Price SICAV USSmallCoEqS USD | 4.21B | 7.81 | 2.21 | - | ||
TRGlobal Focused Growth Equity Funu | 4.08B | 15.61 | 0.43 | 12.72 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Capital Group New Perspective Fuzdu | 15.52B | 14.33 | 1.41 | 10.58 | ||
Capital Group New Perspective Fuzgu | 15.52B | 14.27 | 1.41 | 10.59 | ||
Capital Group New Perspective Fubu | 15.52B | 13.60 | 0.67 | 9.71 | ||
Capital Group New Perspective Fubdu | 15.52B | 13.59 | 0.65 | 9.71 | ||
LU2097333152 | 15.52B | 14.48 | 1.57 | - |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Eli Lilly | US5324571083 | 5.89 | 749.92 | -0.46% | |
Microsoft | US5949181045 | 4.08 | 412.87 | -0.43% | |
Apple | US0378331005 | 4.02 | 228.52 | -0.21% | |
AMD | US0079031078 | 3.23 | 137.49 | -0.08% | |
ConocoPhillips | US20825C1045 | 2.91 | 111.90 | -1.35% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Neutral | Buy | Buy |
Technical Indicators | Strong Sell | BUY | Strong Buy |
Summary | Sell | Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review